×

Please Remove Adblock
Adverts are the main source of Revenue for DoveMed. Please remove adblock to help us create the best medical content found on the Internet.

Interim Influenza Vaccination Recommendations: 2004-05

Last updated March 18, 2020

Approved by: Krish Tangella MD, MBA, FCAP

On October 5, 2004, CDC was notified by Chiron Corporation that none of its influenza vaccine (Fluvirin®) would be available for distribution in the United States for the 2004-05 influenza season. The company indicated that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, where Chiron's Fluvirin vaccine is produced, has suspended the company's license to manufacture Fluvirin vaccine in its Liverpool facility for 3 months, preventing any release of this vaccine for this influenza season. This will reduce by approximately one half the expected supply of trivalent inactivated vaccine (flu shot) available in the United States for the 2004-05 influenza season.


Interim Influenza Vaccination Recommendations: 2004-05

On October 5, 2004, CDC was notified by Chiron Corporation that none of its influenza vaccine (Fluvirin®) would be available for distribution in the United States for the 2004-05 influenza season. The company indicated that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, where Chiron's Fluvirin vaccine is produced, has suspended the company's license to manufacture Fluvirin vaccine in its Liverpool facility for 3 months, preventing any release of this vaccine for this influenza season. This will reduce by approximately one half the expected supply of trivalent inactivated vaccine (flu shot) available in the United States for the 2004-05 influenza season.

The remaining supply of influenza vaccine that is expected to be available in the United States this season is nearly 54 million doses of Fluzone®, (inactivated flu shot) manufactured by Aventis Pasteur, Inc. Of these doses, approximately 30 million doses already have been distributed by Aventis Pasteur. In addition, approximately 1.1 million doses of live attenuated influenza vaccine (LAIV/Flumist®) manufactured by MedImmnune will be available this season.

Because of this urgent situation, CDC, in coordination with its Advisory Committee for Immunization Practices (ACIP), is issuing interim recommendations for influenza vaccination during the 2004-05 season. These interim recommendations were formally recommended by ACIP on October 5, 2004 and take precedence over earlier recommendations.

Priority Groups for Influenza Vaccination

Priority groups for vaccination with inactivated influenza vaccine this season are:

all children aged 6-23 months,

adults aged 65 years and older,

persons aged 2-64 years with underlying chronic medical conditions,

all women who will be pregnant during influenza season,

residents of nursing homes and long-term care facilities,

children 6 months-18 years of age on chronic aspirin therapy,

health-care workers with direct patient care, and

out-of-home caregivers and household contacts of children aged <6 months.

Other Vaccination Recommendations

Persons in priority groups identified above should be encouraged to search locally for vaccine if their regular health-care provider does not have vaccine available.

Intranasally administered, live, attenuated influenza vaccine, if available, should be encouraged for healthy persons who are aged 5–49 years and are not pregnant, including health-care workers (except those who care for severely immunocompromised patients in special care units) and persons caring for children aged <6 months.

Certain children aged <9 years require 2 doses of vaccine if they have not previously been vaccinated. All children at high risk for complications from influenza, including those aged 6–23 months, who present for vaccination, should be vaccinated with a first or second dose, depending on vaccination status. However, doses should not be held in reserve to ensure that 2 doses will be available. Instead, available vaccine should be used to vaccinate persons in priority groups on a first-come, first-serve basis.

Vaccination of Persons in Nonpriority Groups

Persons who are not included in one of the priority groups above should be informed about the urgent vaccine supply situation and asked to forego or defer vaccination.

Persons Who Should Not Receive Influenza Vaccine

Persons in the following groups should not receive influenza vaccine before talking with their doctor:

persons with a severe allergy (i.e., anaphylactic allergic reaction) to hens' eggs and

persons who previously had onset of Guillain-Barré syndrome during the 6 weeks after receiving influenza vaccine.

For more information, visit www.cdc.gov/flu or call the National Immunization Hotline at (800) 232-2522 (English), (800) 232-0233 (Español), or (800) 243-7889 (TTY).

References and Information Sources used for the Article:


Materials:


Reviewed and Approved by a member of the DoveMed Editorial Board
First uploaded: March 18, 2020
Last updated: March 18, 2020